Retatrutide engages three receptor pathways at once — GLP-1, GIP and glucagon — which is why it is described as a "triple agonist" and has produced the largest weight-reduction figures on record in its Phase 3 TRIUMPH program (research context only). Cagrilintide works through an entirely separate pathway: the amylin receptor (CALCR/RAMP complex), a non-GLP-1, non-GIP, non-glucagon mechanism for appetite regulation.
Because their mechanisms do not overlap, Cagrilintide is frequently studied alongside a GLP-1 or a triple agonist for additive rather than competitive effects. That is the logic behind CagriSema (Cagrilintide + Semaglutide) and the interest in Retatrutide + Cagrilintide ("RetaCagri") combinations. The amylin pathway complements incretin signaling instead of duplicating it.
| Retatrutide | Cagrilintide | |
|---|---|---|
| Class | Triple agonist | Amylin analog |
| Pathways | GLP-1 + GIP + glucagon | Amylin (CALCR/RAMP) |
| Often used | Standalone | In combination (e.g. CagriSema) |
| Research status | Phase 3 (TRIUMPH) | Studied standalone & combined |
Both are tracked on PepsTracker across all 26 vendors and normalized to cost-per-milligram with discount codes applied. Compare live:
Vendors including Platinum Peptides carry both compounds (plus a Sema/Cagri blend), with 15% off via code pepstracker15.
Retatrutide is a triple agonist that activates GLP-1, GIP and glucagon receptors. Cagrilintide is an amylin analog that works through the separate amylin (CALCR/RAMP) pathway. They engage different mechanisms and are often studied together rather than as substitutes.
In research, amylin analogs like Cagrilintide are combined with incretin agonists for additive effects (as in CagriSema). Retatrutide + Cagrilintide ("RetaCagri") is studied on the same rationale. These are research chemicals for laboratory use only.
It depends on vendor and vial size. PepsTracker normalizes both to cost-per-milligram after discount codes across 26 vendors so you can see the current cheapest source.